2024
Hepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among U.S. Veterans with Chronic Hepatitis B
Wong R, Yang Z, Jou J, John B, Lim J, Cheung R. Hepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among U.S. Veterans with Chronic Hepatitis B. Gastro Hep Advances 2024 DOI: 10.1016/j.gastha.2024.10.015.Peer-Reviewed Original ResearchChronic hepatitis B patientsChronic hepatitis BLiver-related outcomesHepatic decompensationHepatitis delta virusCohort of U.S. veteransNational cohortU.S. veteransRisk of cirrhosisIncidence of cirrhosisPositive patientsHDV infectionHepatitis BEvaluate incidenceHepatocellular carcinomaCirrhosisPatientsDecompensationVirus testingPropensity scoreHepatitisDelta virusNelson-Aalen methodDiagnosisOutcomesAn explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis
Njei B, Osta E, Njei N, Al-Ajlouni Y, Lim J. An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis. Scientific Reports 2024, 14: 8589. PMID: 38615137, PMCID: PMC11016071, DOI: 10.1038/s41598-024-59183-4.Peer-Reviewed Original ResearchConceptsNational Health and Nutrition Examination SurveyRisk of progression to cirrhosisClinical risk indexHealth and Nutrition Examination SurveyControlled attenuation parameter valuesNovel therapeutic optionsLiver stiffness measurementProgression to cirrhosisAspartate aminotransferase levelsNutrition Examination SurveyResource-limited settingsFIB-4Fibrosis scorePlatelet countAminotransferase levelsTherapeutic optionsWaist circumferenceClinically applicable modelExamination SurveyNonalcoholic steatohepatitisFAST scoreEarly identificationElastography measurementsStiffness measurementPatients
2023
Clinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention
Lim J, Njei B. Clinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention. Hepatic Medicine Evidence And Research 2023, 15: 151-164. PMID: 37814605, PMCID: PMC10560482, DOI: 10.2147/hmer.s385133.Peer-Reviewed Original ResearchAcute liver injuryCOVID-19 patientsPre-existing chronic liver diseaseCOVID-19Chronic liver diseaseSARS-CoV-2Immune dysregulationSupportive careBiliary dysfunctionHepatic injuryLiver injuryVascular changesLiver diseaseClinical manifestationsSignificant complicationsLong-term effectsDiagnostic criteriaTherapeutic targetCholangiopathyDiagnostic advancementsPatientsGlobal healthCOVID-19 pandemicInjuryDiverse manifestationsSa1523 ON-TREATMENT RISK OF HEPATOCELLULAR CARCINOMA DOES NOT DIFFER BY BASELINE HEPATITIS B VIRAL LOAD AMONG A LARGE COHORT OF PREDOMINANTLY NON-ASIAN PATIENTS WITH NON-CIRRHOTIC E ANTIGEN NEGATIVE CHRONIC HEPATITIS B
Yang Z, Cheung R, Jou J, Lim J, Wong R. Sa1523 ON-TREATMENT RISK OF HEPATOCELLULAR CARCINOMA DOES NOT DIFFER BY BASELINE HEPATITIS B VIRAL LOAD AMONG A LARGE COHORT OF PREDOMINANTLY NON-ASIAN PATIENTS WITH NON-CIRRHOTIC E ANTIGEN NEGATIVE CHRONIC HEPATITIS B. Gastroenterology 2023, 164: s-399-s-400. DOI: 10.1016/s0016-5085(23)01924-8.Peer-Reviewed Original Research